home / stock / cue / cue news

CUE News and Press, Cue Biopharma Inc. From 06/10/21

Stock Information
Company Name: Cue Biopharma Inc.
Stock Symbol: CUE
Market: NASDAQ
Website: cuebiopharma.com
Menu
CUE CUE Quote CUE Short CUE News CUE Articles CUE Message Board
Get CUE Alerts

News, Short Squeeze, Breakout and More Instantly...
CUE - Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer

Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the recommended Phase 2 dose of 4mg/kg. The multi-center, open-label study...
CUE - Cue Biopharma doses the first patient in trial for CUE-101 in head and neck cancer

Chinnapong/iStock via Getty Images Massachusetts-based clinical-stage Cue Biopharma (CUE) announced the dosing of the first patient in Part B expansion phase of its Phase 1 study for CUE-101 as monotherapy at the recommended Phase 2 dose of 4mg/kg. The multi-center, open-label study...

CUE - Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...

CUE - Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...
CUE - Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, anno...

CUE - Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript

Cue Biopharma, Inc. (CUE) Q1 2021 Earnings Conference Call May 17, 2021, 04:30 PM ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Mat...

CUE - Cue Biopharma EPS misses by $0.02, beats on revenue

Cue Biopharma (CUE): Q1 GAAP EPS of -$0.41 misses by $0.02.Revenue of $1.55M (+72.2% Y/Y) beats by $0.94M.“We finished the first quarter of 2021 in a solid financial position which was further strengthened by the deployment of our at-the-market common stock facility in April that enabl...
CUE - Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business an...

CUE - PRTY, TTD, PRPO and WKHS among midday movers

Gainers: Protagenic Therapeutics (PTIX) +67%.Obalon Therapeutics (OBLN) +57%.Precipio (PRPO) +35%.Cue Biopharma (CUE) +31%.SemiLEDs (LEDS) +28%.CKX Lands (CKX) +27%.Tecnoglass (TGLS) +24%.Soliton (SOLY) +24%.Party City Holdco (PRTY) +19%.uCloudlink (UCL) +16%.Losers: Rekor...

CUE - Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients

Cue Biopharma (CUE) gains 8% premarket after announcing interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSC...
Previous 10 Next 10